Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Diabetes Care|July 12, 2014
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetesRonnie Aronson, Peter A Gottlieb, Jens S Christiansen, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trialRonnie Aronson, Ruth E Brown, Lisa Chu, et al.
Diabetes Care|May 1, 2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Matthew C Riddle, Ronnie Aronson, Philip Home, et al.
Diabetes Care|March 3, 2022
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical TrialThomas R Pieber, Ronnie Aronson, Ulrike Hövelmann, et al.
Health and Quality of Life Outcomes|January 21, 2021
Reliability and validity of the Chinese version of the LMC Skills, Confidence & Preparedness Index (SCPI) in patients with type 2 diabetesXimin Wang, Weibo Lyu, Ronnie Aronson, et al.
Diabetes, Obesity & Metabolism|March 28, 2023
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitusRonnie Aronson, Torben Biester, Jennifer Leohr, et al.
BMJ Open Diabetes Research & Care|June 23, 2020
Validation of a type 1 diabetes algorithm using electronic medical records and administrative healthcare data to study the population incidence and prevalence of type 1 diabetes in Ontario, CanadaAlanna Weisman, Karen Tu, Jacqueline Young, et al.
Diabetes Care|December 4, 2016
Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)Harpreet S Bajaj, Karri Venn, Chenglin Ye, et al.
Diabetes, Obesity & Metabolism|May 15, 2020
Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCTHarpreet S Bajaj, Ruth E Brown, Dishay Jiandani, et al.
Diabetes Care|August 17, 2016
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized TrialJulio Rosenstock, Ronnie Aronson, George Grunberger, et al.
Pageof 7